Oncimmune Holdings plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ONC.L research report →
Companywww.oncimmune.com
Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a immunodiagnostic test for detecting and identifying lung cancer. The company also develops SeroTag, a platform that is used to discover and validate biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel.
- CEO
- Martin John Gouldstone
- IPO
- 2016
- Employees
- 40
- HQ
- Nottingham, GB
Price Chart
Valuation
- Market Cap
- $1.27M
- P/E
- -0.23
- P/S
- 0.47
- P/B
- -0.35
- EV/EBITDA
- -1.85
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 44.94%
- Op Margin
- -117.78%
- Net Margin
- -132.46%
- ROE
- 416.53%
- ROIC
- -69.94%
Growth & Income
- Revenue
- $2.74M · 137.76%
- Net Income
- $-3,628,000 · -188.40%
- EPS
- $-0.05 · -186.40%
- Op Income
- $-3,226,000
- FCF YoY
- 50.31%
Performance & Tape
- 52W High
- $31.00
- 52W Low
- $0.01
- 50D MA
- $2.54
- 200D MA
- $11.63
- Beta
- 1.81
- Avg Volume
- 357.44K
Get TickerSpark's AI analysis on ONC.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ONC.L Coverage
We haven't published any research on ONC.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ONC.L Report →